NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma
Phase 2
Completed
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020397
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00052728
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸NCI - Center for Cancer Research, Bethesda, Maryland, United States
Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020332
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Phase 1
Completed
- Conditions
- B-cell Adult Acute Lymphoblastic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaNoncontiguous Stage II Adult Burkitt LymphomaNoncontiguous Stage II Adult Diffuse Large Cell LymphomaNoncontiguous Stage II Adult Diffuse Mixed Cell LymphomaNoncontiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaNoncontiguous Stage II Adult Immunoblastic Large Cell LymphomaNoncontiguous Stage II Adult Lymphoblastic LymphomaNoncontiguous Stage II Grade 1 Follicular Lymphoma
- Interventions
- Biological: rituximabBiological: aldesleukinOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00010192
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Inflammatory Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
- Interventions
- Biological: filgrastimProcedure: therapeutic conventional surgeryOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00049114
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
Phase 2
Terminated
- Conditions
- Recurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT00009984
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Phase 2
Completed
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00041106
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Edrecolomab in Treating Patients With Stage II Colon Cancer
Phase 3
Completed
- Conditions
- Mucinous Adenocarcinoma of the ColonSignet Ring Adenocarcinoma of the ColonStage IIA Colon CancerStage IIB Colon CancerStage IIC Colon Cancer
- Interventions
- Biological: edrecolomabOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2100
- Registration Number
- NCT00002968
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
Phase 2
Completed
- Conditions
- Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00039104
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer
Phase 1
Completed
- Conditions
- Adenocarcinoma of the RectumStage II Rectal CancerStage III Rectal Cancer
- Interventions
- Biological: bevacizumabRadiation: external beam radiation therapyProcedure: therapeutic conventional surgeryOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00052559
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath